Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis

NCT ID: NCT02065622

Last Updated: 2020-11-23

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

952 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-03-27

Study Completion Date

2019-11-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate safety and efficacy of two adalimumab dosing regimens for induction and maintenance (standard and higher dosing) in achieving clinical remission in subjects with moderately to severely active ulcerative colitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis (UC)

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Ulcerative Colitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Induction (Main Study + Japan Sub-study): I-SD

Induction Standard Dose: Double-blind adalimumab regimen of 160 mg at Week 0 followed by 80 mg at Week 2, 40 mg at Week 4, and 40 mg at Week 6.

Group Type EXPERIMENTAL

Adalimumab

Intervention Type DRUG

Placebo

Intervention Type OTHER

Induction (Main Study + Japan Sub-study): I-HD

Induction Higher Dose: Double-blind adalimumab regimen of 160 mg at Weeks 0, 1, 2, and 3 followed by 40 mg at Week 4, and 40 mg at Week 6.

Group Type EXPERIMENTAL

Adalimumab

Intervention Type DRUG

Maintenance (Main Study + Japan Sub-study): M-SD

Maintenance Standard Dose: Double-blind adalimumab 40 mg every other week (eow), for 44 weeks.

Group Type EXPERIMENTAL

Adalimumab

Intervention Type DRUG

Placebo

Intervention Type OTHER

Maintenance (Main Study + Japan Sub-study): M-HD

Maintenance Higher Dose: Double-blind adalimumab 40 mg every week (ew) for 44 weeks.

Group Type EXPERIMENTAL

Adalimumab

Intervention Type DRUG

Maintenance (Main Study): TDM Regimen

Double-blind adalimumab 40 mg eow at Week 8 and Week 10, with possible dose adjustments at Weeks 12, 24, and 37 based on criteria assessing blinded adalimumab serum concentration and rectal bleeding subscore (RBS) assessments.

Group Type EXPERIMENTAL

Adalimumab

Intervention Type DRUG

Placebo

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adalimumab

Intervention Type DRUG

Placebo

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Humira

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of Ulcerative Colitis (UC) for at least 90 days, confirmed by endoscopy during Screening period.
* Active UC with Mayo Score of 6 to 12 points and endoscopy subscore of 2 to 3 despite concurrent or prior treatment with a full and adequate course, in the opinion of the Investigator, with oral corticosteroids or immunosuppressants or both. Mayo Score is confirmed by central reader.

Exclusion Criteria

* Subject with Crohn's disease (CD) or indeterminate colitis (IC).
* Current diagnosis of fulminant colitis and/or toxic megacolon.
* Subjects with disease limited to the rectum (ulcerative proctitis) during the screening endoscopy.
* Chronic recurring infections or active tuberculosis (TB).
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AbbVie

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AbbVie Inc.

Role: STUDY_DIRECTOR

AbbVie

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Digestive Health Specialists of the Southeast /ID# 127844

Dothan, Alabama, United States

Site Status

Ucsd /Id# 122313

La Jolla, California, United States

Site Status

Rocky Mountain Clinical Resear /ID# 122180

Wheat Ridge, Colorado, United States

Site Status

Medical Research Ctr CT /ID# 122179

Hamden, Connecticut, United States

Site Status

Gastro Florida /ID# 170619

Clearwater, Florida, United States

Site Status

Research Associates of South Florida,LLC /ID# 170309

Miami, Florida, United States

Site Status

Gastroenterology Group Naples /ID# 127806

Naples, Florida, United States

Site Status

Shafran Gastroenterology Ctr /ID# 122320

Winter Park, Florida, United States

Site Status

Atlanta Gastro Assoc /ID# 122336

Atlanta, Georgia, United States

Site Status

Gastro Assoc of Central GA /ID# 122318

Macon, Georgia, United States

Site Status

Northwestern University Feinberg School of Medicine /ID# 122183

Chicago, Illinois, United States

Site Status

University of Chicago /ID# 122302

Chicago, Illinois, United States

Site Status

Carle Foundation Hospital /ID# 135955

Urbana, Illinois, United States

Site Status

Louisiana Research Ctr. LLC /ID# 141655

Shreveport, Louisiana, United States

Site Status

University of Maryland Med Ctr /ID# 169734

Baltimore, Maryland, United States

Site Status

MGG Group, Inc.Chevy Chase Clinical Research /ID# 122238

Chevy Chase, Maryland, United States

Site Status

University of Michigan Hospitals /ID# 122240

Ann Arbor, Michigan, United States

Site Status

Mayo Clinic - Rochester /ID# 122244

Rochester, Minnesota, United States

Site Status

Ctr for Digest and Liver Dis /ID# 122182

Mexico, Missouri, United States

Site Status

NYU Langone Long Island CRA /ID# 122177

Great Neck, New York, United States

Site Status

Icahn School of Med Mt. Sinai /ID# 127047

New York, New York, United States

Site Status

Charlotte Gastro Hepatology /ID# 122235

Charlotte, North Carolina, United States

Site Status

Wake Research Associates, LLC /ID# 122157

Raleigh, North Carolina, United States

Site Status

Consultants for Clinical Res /ID# 122304

Cincinnati, Ohio, United States

Site Status

Dayton Gastroenterology, Inc. /ID# 127804

Englewood, Ohio, United States

Site Status

Gastro United of Tulsa /ID# 125436

Tulsa, Oklahoma, United States

Site Status

The Oregon Clinic- Gastro West /ID# 135273

Portland, Oregon, United States

Site Status

University of Pittsburgh MC /ID# 122331

Pittsburgh, Pennsylvania, United States

Site Status

Erlanger Institute for Clinica /ID# 129009

Chattanooga, Tennessee, United States

Site Status

Gastro One /ID# 122339

Germantown, Tennessee, United States

Site Status

Vanderbilt Univ Med Ctr /ID# 125496

Nashville, Tennessee, United States

Site Status

DHAT Research Institute /ID# 170616

Garland, Texas, United States

Site Status

Biopharma Informatic Research /ID# 171150

Houston, Texas, United States

Site Status

Austin Center for Clinical Research /ID# 125396

Pflugerville, Texas, United States

Site Status

Texas Digestive Disease Consul /ID# 141677

Southlake, Texas, United States

Site Status

Texas Digestive Disease Consul /ID# 141678

Southlake, Texas, United States

Site Status

Advanced Research Institute /ID# 126147

Ogden, Utah, United States

Site Status

University of Utah /ID# 122333

Salt Lake City, Utah, United States

Site Status

New River Valley Research Inst /ID# 127801

Christiansburg, Virginia, United States

Site Status

University of Washington /ID# 169721

Seattle, Washington, United States

Site Status

WI Center for Advanced Res /ID# 122178

Milwaukee, Wisconsin, United States

Site Status

Froedtert & the Medical College of Wisconsin /ID# 122261

Milwaukee, Wisconsin, United States

Site Status

KH der Elisabethinen Linz GmbH /ID# 127184

Linz, Upper Austria, Austria

Site Status

Medizinische Universitat Wien /ID# 127186

Vienna, Vienna, Austria

Site Status

Ordination Hainburg an der Don /ID# 127185

Hainburg an der Donau, , Austria

Site Status

Universitaetsklinik fuer Innere Medizin 1 /ID# 125944

Salzburg, , Austria

Site Status

KH der Barmherzigen Brueder /ID# 127183

Sankt Veit an der Glan, , Austria

Site Status

AZ Sint-Lucas /ID# 127187

Ghent, , Belgium

Site Status

UZ Leuven /ID# 126739

Leuven, , Belgium

Site Status

CHU de Liege /ID# 126740

Liège, , Belgium

Site Status

University of Calgary /ID# 125715

Calgary, Alberta, Canada

Site Status

Zeidler Ledcor Centre /ID# 125713

Edmonton, Alberta, Canada

Site Status

Winnipeg Regional Health Autho /ID# 125712

Winnipeg, Manitoba, Canada

Site Status

Qe Ii Hsc /Id# 127045

Halifax, Nova Scotia, Canada

Site Status

London Health Sciences Centre /ID# 127055

London, Ontario, Canada

Site Status

Mount Sinai Hosp.-Toronto /ID# 126590

Toronto, Ontario, Canada

Site Status

Toronto Digestive Disease Asso /ID# 127075

Vaughan, Ontario, Canada

Site Status

McGill Univ HC /ID# 127046

Montreal, Quebec, Canada

Site Status

Hepato-Gastroenterologie HK s.r.o. /ID# 127188

Hradec Králové, , Czechia

Site Status

ISCARE a.s. /ID# 127837

Prague, , Czechia

Site Status

Herlev Hospital /ID# 127191

Herlev, Capital Region, Denmark

Site Status

Regionhospital Silkeborg /ID# 127190

Silkeborg, , Denmark

Site Status

CHRU Lille - Hôpital Claude Huriez /ID# 127197

Lille, Hauts-de-France, France

Site Status

CHU NANCY - Hôpital Brabois Adultes /ID# 127196

Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France

Site Status

CHU Amiens Picardie /ID# 127194

Amiens, Somme, France

Site Status

CHU Estaing /ID# 127848

Clermont-Ferrand, , France

Site Status

CHU Dijon /ID# 127861

Dijon, , France

Site Status

CHU de Grenoble - Albet Michal /ID# 127195

Grenoble, , France

Site Status

CHU Saint ELOI /ID# 169007

Montpellier, , France

Site Status

CHU de Nice /ID# 127193

Nice, , France

Site Status

CHU de Saint-Etienne, Hopital Nord /ID# 134490

Saint-Etienne, , France

Site Status

Hopital Rangueil /ID# 127192

Toulouse, , France

Site Status

Universitatsklinik Regensburg /ID# 201265

Regensburg, Bavaria, Germany

Site Status

Universitatsklinikum Frankfurt /ID# 170300

Frankfurt am Main, Hesse, Germany

Site Status

Univ Hosp Schleswig-Holstein, Campus Kiel, Klinik furer Innere Medizin /ID# 127199

Kiel, Schleswig-Holstein, Germany

Site Status

Charite Universitatsmedizin Berlin Campus Virchow Klinikum /ID# 127203

Berlin, , Germany

Site Status

Mross, Berlin, DE /ID# 127201

Berlin, , Germany

Site Status

Gastrostudien GbR /ID# 169246

Berlin, , Germany

Site Status

Asklepios Westklinikum Hamburg /ID# 127198

Hamburg, , Germany

Site Status

Universitaetsklinikum Jena /ID# 127205

Jena, , Germany

Site Status

EUGASTRO GmbH /ID# 127202

Leipzig, , Germany

Site Status

Universitatsklinikum Magdeburg /ID# 127200

Magdeburg, , Germany

Site Status

Gastro Campus Research GbR /ID# 126743

Münster, , Germany

Site Status

Pecsi Tudomanyegyetem Klinikai Kozpont I. sz. Belgyogyaszati Klinika /ID# 127209

Pécs, Pecs, Hungary

Site Status

Magyar Elhizastudomanyi KKft. /ID# 126589

Budapest, , Hungary

Site Status

Pannonia Maganorvosi Centrum Kft. /ID# 127207

Budapest, , Hungary

Site Status

Szegedi Tudomanyegyetem /ID# 127208

Szeged, , Hungary

Site Status

Rabin Medical Center /ID# 127212

Petakh Tikva, Tel Aviv, Israel

Site Status

Tel Aviv Sourasky Medical Center /ID# 201365

Tel Aviv, Tel Aviv, Israel

Site Status

Soroka University Medical Center /ID# 127213

Beersheba, , Israel

Site Status

Hadassah University Hospital /ID# 127211

Jerusalem, , Israel

Site Status

Kaplan Medical Center /ID# 127210

Rehovot, , Israel

Site Status

A.O.U. Policlinico S.Orsola-Malpighi /ID# 129322

Bologna, Emilia-Romagna, Italy

Site Status

Azienda Ospedaliera San Camillo Forlanini /ID# 127216

Rome, Lazio, Italy

Site Status

Policlinico Agostino Gemelli /ID# 127217

Rome, Lazio, Italy

Site Status

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 127138

Milan, Lombardy, Italy

Site Status

IBD Center - IRCCS Istituto Clinico Humanitas /ID# 127215

Rozzano, Milano, Italy

Site Status

Azienda Ospedaliera Spedali Civili /ID# 127236

Brescia, , Italy

Site Status

Universita di Padova /ID# 127214

Padua, , Italy

Site Status

Ospedali Riuniti Villa Sofia-C /ID# 129323

Palermo, , Italy

Site Status

Policlinico Univ Tor Vergata /ID# 129321

Rome, , Italy

Site Status

IRCCS Casa Sollievo /ID# 127811

San Giovanni Rotondo, , Italy

Site Status

Yokoyama IBD Clinic /ID# 151560

Nagoya, Aichi-ken, Japan

Site Status

Nagoya City University Hospital /ID# 124517

Nagoya, Aichi-ken, Japan

Site Status

Toho University Sakura Medical Center /ID# 124497

Sakura-shi, Chiba, Japan

Site Status

Fukuoka University Chikushi Hospital /ID# 124155

Chikushino-shi, Fukuoka, Japan

Site Status

Kyushu University Hospital /ID# 124495

Fukuoka, Fukuoka, Japan

Site Status

Hidaka Clinic of Coloproctology /ID# 125477

Kurume, Fukuoka, Japan

Site Status

Kurume University Hospital /ID# 125275

Kurume-shi, Fukuoka, Japan

Site Status

Hiroshima University Hospital /ID# 124496

Hiroshima, Hiroshima, Japan

Site Status

Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital /ID# 124480

Sapporo, Hokkaido, Japan

Site Status

Aoyama Clinic /ID# 127836

Kobe, Hyōgo, Japan

Site Status

Hyogo College of Medicine College Hospital /Id# 127539

Nishinomiya-shi, Hyōgo, Japan

Site Status

Kitasato University Hospital /ID# 137694

Sagamihara-shi, Kanagawa, Japan

Site Status

COLO-PROCTOLOGY CENTER Matsushima Clinic /ID# 148423

Yokohama, Kanagawa, Japan

Site Status

Susaki Kuroshio Hospital /ID# 125202

Susaki-shi, Kochi, Japan

Site Status

Japanese Red Cross Kyoto Daiichi Hos /ID# 127540

Kyoto, Kyoto, Japan

Site Status

Osaka Medical College Hospital /ID# 126451

Takatsuki-shi, Osaka, Japan

Site Status

Saitama Medical Center /ID# 128875

Kawagoe-shi, Saitama, Japan

Site Status

Shiga University of Medical Science Hospital /ID# 127675

Ōtsu, Shiga, Japan

Site Status

Hamamatsu South Hospital /ID# 124481

Hamamatsu, Shizuoka, Japan

Site Status

Medical Hospital of Tokyo Medical and Dental University /ID# 128315

Bunkyo-ku, Tokyo, Japan

Site Status

Kitasato Univ Kitasato Inst Ho /ID# 127001

Minato-ku, Tokyo, Japan

Site Status

Kyorin University Hospital /ID# 148184

Mitaka-shi, Tokyo, Japan

Site Status

Wakayama Medical University /ID# 124635

Wakayama, Wakayama, Japan

Site Status

Tokyo Yamate Medical Center /ID# 125201

Tokyo, , Japan

Site Status

Academisch Medisch Centrum /ID# 126741

Amsterdam, North Holland, Netherlands

Site Status

Szpital Uniwersytecki Nr 2 im. dr J.Biziela w Bydgoszczy /ID# 127141

Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

Site Status

Centrum Zdrowia MDM /ID# 170303

Warsaw, Masovian Voivodeship, Poland

Site Status

Endoterapia PFG Sp. z.o.o. /ID# 126513

Warsaw, Masovian Voivodeship, Poland

Site Status

Centrum Medyczne Pratia Gdynia /ID# 170301

Gdynia, Pomeranian Voivodeship, Poland

Site Status

NZOZ All-Medicus /ID# 128740

Katowice, Silesian Voivodeship, Poland

Site Status

H-T.Centrum Medyczne-Endoterapia /ID# 170305

Tychy, Silesian Voivodeship, Poland

Site Status

Centrum Medyczne LukaMed Joanna Luka /ID# 170302

Chojnice, , Poland

Site Status

Centrum Medyczne Sw. Lukaza /ID# 126515

Częstochowa, , Poland

Site Status

Centrum Diagnostyczno Lecznicze Barska /ID# 170304

Lodz, , Poland

Site Status

KO-Med Centra Kliniczne Pulawy /ID# 127219

Puławy, , Poland

Site Status

NZOZ Vivamed /ID# 127218

Warsaw, , Poland

Site Status

C.M. Szpital Swietej Rodziny /ID# 127838

Lodz, Łódź Voivodeship, Poland

Site Status

Institutul Clinic Fundeni /ID# 127839

Sector 2, București, Romania

Site Status

CMDTA Neomed SRL /ID# 127142

Brasov, , Romania

Site Status

Spitalul Clinic Judetean de Urgenta /ID# 125418

Cluj-Napoca, , Romania

Site Status

Tvm Med Serv Srl /Id# 127221

Cluj-Napoca, , Romania

Site Status

Cabinet Medical Dr. Fratila SRL, Specialitatea Medicina Interna /ID# 127002

Oradea, , Romania

Site Status

Salvo-San-Ciobanca SRL /ID# 127140

Zalău, , Romania

Site Status

Gastroenterologicke centrum ASSIDUO a IBD centrum /ID# 127222

Bratislava, , Slovakia

Site Status

Gastroenterologicka Ambulancia /ID# 125632

Bratislava, , Slovakia

Site Status

Vseobecna Nemocnica s poliklinikou Lucenec /ID# 127322

Lučenec, , Slovakia

Site Status

Hospital General Universitario de Alicante /ID# 129261

Alicante, , Spain

Site Status

Hospital Clinic de Barcelona /ID# 138147

Barcelona, , Spain

Site Status

Complejo Hospitalario Universitario de Ferrol /ID# 127840

Ferrol, , Spain

Site Status

Hospital Univ Dr. Negrin /ID# 127841

Las Palmas de Gran Canaria, , Spain

Site Status

Hospital Univ de la Princesa /ID# 135828

Madrid, , Spain

Site Status

Hospital General Universitario Gregorio Maranon /ID# 127224

Madrid, , Spain

Site Status

Hosp Univ 12 de Octubre /ID# 129257

Madrid, , Spain

Site Status

Hospital Universitario La Paz /ID# 127223

Madrid, , Spain

Site Status

Hosp Clin Univ de Valencia /ID# 170306

Valencia, , Spain

Site Status

Hosp Clin Univ Lozano Blesa /ID# 129255

Zaragoza, , Spain

Site Status

Kantonsspital St. Gallen /ID# 127843

Sankt Gallen, Canton of St. Gallen, Switzerland

Site Status

University Hospital Zurich /ID# 127842

Zurich, Canton of Zurich, Switzerland

Site Status

GI National Institute of Therapy named by L.T. Malaya /ID# 127231

Kharkiv, Kharkivs’ka Oblast’, Ukraine

Site Status

Public Institution Kherson City Clinical Hospital named after le.le. Karabelesh /ID# 127233

Kherson, , Ukraine

Site Status

Municipal Clinical Hospital #8 /ID# 127235

Kiev, , Ukraine

Site Status

Lviv City Clinical Hospital NO.4 /ID# 127232

Lviv, , Ukraine

Site Status

CNPE City Hospital No.6 of Zaporizhzhia City Counsil /ID# 127137

Zaporizhzhia, , Ukraine

Site Status

Royal Hampshire County Hosp /ID# 169250

Winchester, Hampshire, United Kingdom

Site Status

Norfolk and Norwich Univ Hosp /ID# 127139

Norwich, Norfolk, United Kingdom

Site Status

Western General Hospital /ID# 204801

Edinburgh, , United Kingdom

Site Status

St. Mark's Hospital /ID# 127226

Harrow, , United Kingdom

Site Status

Hull and East Yorkshire Hospitals NHS Trust /ID# 127225

Hull, , United Kingdom

Site Status

Oxford University Hospitals NHS Foundation Trust The John Radcliffe Hospital /ID# 129324

Oxford, , United Kingdom

Site Status

Southampton General Hospital /ID# 127228

Southampton, , United Kingdom

Site Status

The Royal Wolverhampton NHS Tr /ID# 127227

Wolverhampton, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Belgium Canada Czechia Denmark France Germany Hungary Israel Italy Japan Netherlands Poland Romania Slovakia Spain Switzerland Ukraine United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Reppell M, Zheng X, Dreher I, Blaes J, Regan E, Haslberger T, Guay H, Pivorunas V, Smaoui N. HLA-DQA1*05 Associates With Anti-Tumor Necrosis Factor Immunogenicity and Low Adalimumab Trough Concentrations in Inflammatory Bowel Disease Patients From the SERENE Ulcerative Colitis and Crohn's Disease Studies. J Crohns Colitis. 2025 Jan 11;19(1):jjae129. doi: 10.1093/ecco-jcc/jjae129.

Reference Type DERIVED
PMID: 39162746 (View on PubMed)

Verstockt B, Pivorunas V, Al Mahi N, Smaoui N, Guay H, Kennedy NA, Goodhand JR, Lin S, Bai BYH, Hanauer SB, Ferrante M, Panes J, Vermeire S. Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies. J Crohns Colitis. 2024 Apr 23;18(4):493-505. doi: 10.1093/ecco-jcc/jjad170.

Reference Type DERIVED
PMID: 37801628 (View on PubMed)

Ponce-Bobadilla AV, Stodtmann S, Chen MJ, Winzenborg I, Mensing S, Blaes J, Haslberger T, Laplanche L, Dreher I, Mostafa NM. Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis. Clin Pharmacokinet. 2023 Apr;62(4):623-634. doi: 10.1007/s40262-023-01221-x. Epub 2023 Mar 11.

Reference Type DERIVED
PMID: 36905528 (View on PubMed)

Greener T, Boland K, Milgrom R, Ben-Bassat O, Steinhart AH, Silverberg MS, Narula N. Higher adalimumab maintenance regimen is more effective than standard dose in anti-TNF experienced Crohn's disease patients. Eur J Gastroenterol Hepatol. 2021 Oct 1;33(10):1274-1279. doi: 10.1097/MEG.0000000000002250.

Reference Type DERIVED
PMID: 34402466 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2013-001682-16

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

M14-033

Identifier Type: -

Identifier Source: org_study_id